A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

Project: Research project

Project Details

StatusActive
Effective start/end date10/25/198/31/50

Funding

  • MedImmune, Inc.